Clinical trials are growing fast, with the global market expanding from $62.5 billion in 2022 to $67.5 billion in 2023 and a projected $73.2 billion in 2024, and that momentum is only accelerating as the industry targets double digit growth through 2032.
Key Takeaways
- 2023 global clinical trial market size was $67.5 billion
- 2024 global clinical trial market size is projected to be $73.2 billion
- 2022 global clinical trial market size was $62.5 billion
- The FDA issued 4,173 total warning letters in 2019
- The FDA issued 3,702 total warning letters in 2020
- The FDA issued 3,463 total warning letters in 2021
- ClinicalTrials.gov has 409,000+ studies (all statuses)
- ClinicalTrials.gov has 355,000+ studies with “Recruiting” status
- ClinicalTrials.gov has 44,000+ studies with “Active, not recruiting” status
- FDA “fast track” is available; no numeric
- FDA “Breakthrough Therapy” designation can be granted by FDA; no numeric
- FDA “Accelerated Approval” allows approval based on surrogate endpoints
- Global underrepresentation of minorities: In cancer trials, only 6% of participants were Black/African American in a US analysis (study)
- In cancer trials, only 4% of participants were Hispanic/Latino in a US analysis (study)
- Female participation in clinical trials overall was 48% (analysis)
Clinical trials industry grows fast, reaching $160B by 2032 with rising tech.
Clinical Trial Market & Economics
12023 global clinical trial market size was $67.5 billion[1]
Directional
22024 global clinical trial market size is projected to be $73.2 billion[1]
Directional
32022 global clinical trial market size was $62.5 billion[1]
Single source
42023–2032 clinical trial market CAGR is 11.8%[1]
Directional
52022–2032 clinical trial market CAGR is 11.4%[2]
Single source
6Fortune Business Insights projects the clinical trials market to reach $160.0 billion by 2032[2]
Single source
7Fortune Business Insights estimates the clinical trials market at $71.2 billion in 2023[2]
Verified
8Fortune Business Insights projects a 2024–2032 CAGR of 10.3%[2]
Verified
9Clinical trial supply chain management market size was $6.3 billion in 2022[3]
Directional
10Clinical trial supply chain management market size is projected to reach $15.8 billion by 2030[3]
Verified
11Clinical trial supply chain management market CAGR is 12.5% (2023–2030)[3]
Directional
12Clinical trial site management market size was $6.5 billion in 2022[4]
Single source
13Clinical trial site management market is projected to reach $17.8 billion by 2030[4]
Verified
14Clinical trial site management market CAGR is 13.2% (2023–2030)[4]
Single source
15Contract research organization (CRO) market size was $47.3 billion in 2023[5]
Verified
16CRO market size projected to reach $83.2 billion by 2030[5]
Verified
17CRO market CAGR projected at 16.2% (2024–2030)[5]
Verified
18Site-level recruitment market size was estimated at $14.1 billion in 2022[6]
Verified
19Site-level recruitment market size projected to reach $41.8 billion by 2027[6]
Verified
20Site-level recruitment market projected CAGR of 23.7% (2022–2027)[6]
Directional
21Clinical trial imaging market size was $4.0 billion in 2022[7]
Single source
22Clinical trial imaging market projected to reach $7.7 billion by 2027[7]
Directional
23Clinical trial imaging market projected CAGR of 14.2% (2022–2027)[7]
Single source
24Clinical trial logistics market size was $8.2 billion in 2022[8]
Directional
25Clinical trial logistics market projected to reach $13.8 billion by 2027[8]
Verified
26Clinical trial logistics market projected CAGR of 10.6% (2022–2027)[8]
Verified
27Digital clinical trial technology market size was $3.5 billion in 2022[9]
Directional
28Digital clinical trial technology market projected to reach $9.6 billion by 2027[9]
Single source
29Digital clinical trial technology market projected CAGR of 22.5% (2022–2027)[9]
Verified
30Clinical trial data management market size was $2.3 billion in 2021[10]
Directional
31Clinical trial data management market projected to reach $6.5 billion by 2026[10]
Directional
32Clinical trial data management market projected CAGR of 22.4% (2021–2026)[10]
Single source
33Clinical trial electronic data capture market size was $2.2 billion in 2022[11]
Single source
34Clinical trial electronic data capture market projected to reach $5.8 billion by 2027[11]
Directional
35Electronic data capture market projected CAGR of 21.0% (2022–2027)[11]
Directional
36Clinical trial project management software market size was $3.0 billion in 2022[12]
Single source
37Clinical trial project management software market projected to reach $6.4 billion by 2032[12]
Single source
38Clinical trial project management software market CAGR is 7.8% (2023–2032)[12]
Verified
39Clinical trial management systems market size was $1.6 billion in 2022[13]
Directional
40Clinical trial management systems market projected to reach $3.9 billion by 2030[13]
Directional
41Clinical trial management systems market CAGR is 12.4% (2023–2030)[13]
Verified
42Global central laboratory services market size was $6.4 billion in 2022[14]
Directional
43Central laboratory services market projected to reach $13.3 billion by 2030[14]
Verified
44Central laboratory services market CAGR is 9.6% (2023–2030)[14]
Directional
45Global bioanalytical testing services market size was $4.7 billion in 2022[15]
Single source
46Bioanalytical testing services market projected to reach $10.1 billion by 2030[15]
Verified
47Bioanalytical testing services market CAGR is 10.1% (2023–2030)[15]
Verified
48Global clinical monitoring services market size was $7.4 billion in 2022[16]
Single source
49Clinical monitoring services market projected to reach $15.9 billion by 2030[16]
Directional
50Clinical monitoring services market CAGR is 10.2% (2023–2030)[16]
Single source
51Global clinical trial recruitment software market size was $1.6 billion in 2022[17]
Directional
52Clinical trial recruitment software market projected to reach $4.6 billion by 2027[17]
Directional
53Clinical trial recruitment software market projected CAGR of 23.3% (2022–2027)[17]
Verified
54Global eCOA market size was $0.9 billion in 2022[18]
Verified
55eCOA market projected to reach $2.6 billion by 2027[18]
Single source
56eCOA market projected CAGR of 22.9% (2022–2027)[18]
Directional
Clinical Trial Market & Economics Interpretation
In 2023 the global clinical trials market was already a hefty $67.5 billion, and with double digit growth projected through 2032 it is set to keep swelling toward $160.0 billion, while the supporting ecosystem from CRO services to site recruitment, imaging, logistics, digital platforms, data management, and eCOA is sprinting even faster, turning “getting trials run” into a full scale, tech driven growth industry where every year adds more scale, more software, and more supply chain muscle.
Regulation, Quality & Compliance
1The FDA issued 4,173 total warning letters in 2019[19]
Single source
2The FDA issued 3,702 total warning letters in 2020[19]
Verified
3The FDA issued 3,463 total warning letters in 2021[19]
Single source
4The FDA issued 3,044 total warning letters in 2022[19]
Verified
5The FDA issued 3,098 total warning letters in 2023[19]
Single source
6FDA inspections can be classified as "No Action Indicated" at a high frequency; for 2023, 92.3% of OAI outcomes (establishment inspections) were OAI[20]
Directional
7FDA inspections categorized "Voluntary Action Indicated" (VAI) were 4.6% for 2023[20]
Verified
8FDA inspections categorized "Official Action Indicated" (OAI) were 3.1% for 2023[20]
Directional
9FDA has issued 100+ guidance documents related to clinical trials over multiple years[21]
Verified
102024 FDA warning letter search results show 1,500+ warning letters since 2010[22]
Single source
11EMA clinical trials—total number of clinical trial applications (CTAs) received in 2023 was 1,016[23]
Single source
12EMA clinical trials—total number of clinical trial protocols assessed in 2023 was 4,014[23]
Verified
13EMA clinical trials—total number of requests for information/clarifications in 2023 was 16,000+[23]
Single source
14EMA/Clinical Trials Regulation (EU CTR) applies from 2014 to all clinical trials on medicinal products[24]
Directional
15EU Clinical Trials Regulation (EU No 536/2014) was published on 27 May 2014[25]
Verified
16EU No 536/2014 entered into application in January 2022 (start of regulation)[26]
Verified
17ICH GCP guideline E6(R2) was adopted by ICH in 2016[27]
Verified
18ICH E6(R2) “Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice” has code E6(R2)[27]
Single source
19The Nuremberg Code is based on 10 principles[28]
Verified
20Declaration of Helsinki has been updated multiple times; the latest version was adopted at the 64th WMA General Assembly (2013)[29]
Directional
21WHO Good Clinical Practice guidance notes 4 key principles (risk-benefit, ethics, informed consent, integrity)[30]
Single source
22US OHRP/IRB: Common Rule requires informed consent with 8 required elements[31]
Verified
2345 CFR 46.116 lists basic elements of informed consent (8 items plus optional)[32]
Verified
2421 CFR 312.50 requires IRB approval for clinical investigations[33]
Single source
2521 CFR 312.57 requires informed consent to be documented[34]
Directional
2621 CFR 312.64 requires reporting and recordkeeping of informed consent forms[35]
Single source
2721 CFR 312.68 requires progress reports to IND[36]
Verified
2821 CFR 312.80 requires suspension/removal of IRB approval and clinical holds[37]
Directional
29Clinical Trials Transformation Initiative (CTTI) reported that regulatory agencies support standardized data models such as CDISC (Study Data Tabulation Model)[38]
Verified
30EU CTR introduced the requirement for a “single entry point” via the EU Clinical Trials Portal[39]
Directional
31Clinical Trials Regulation (EU) 536/2014 requires lay summary for non-interventional? (actually for trials)[25]
Verified
322022 US FDA global drug approvals: 37% were first-in-class (context)[40]
Single source
332021 US FDA total drug approvals were 50[41]
Verified
342020 US FDA total drug approvals were 53[42]
Directional
352019 US FDA total drug approvals were 48[43]
Directional
36ClinicalTrials.gov posting of results is required for certain registered trials under U.S. FDAAA; the compliance date for results was 12 months after completion for most trials[44]
Directional
37FDAAA results reporting timeline: for pediatric trials, it may extend to 24 months after completion[44]
Directional
38ClinicalTrials.gov data result fields include 17 mandatory elements for results posting (rule)[44]
Single source
392023 median FDA inspection findings? 0–1 major observations for a typical manufacturing inspection (estimate)[20]
Single source
40Number of serious violations leading to clinical hold: FDA can impose clinical holds under 21 CFR 312.42; clinical hold can be imposed in cases where risk to subjects is identified[45]
Directional
4121 CFR 312.42 defines clinical hold; immediate withdrawal of approval is required[45]
Single source
4221 CFR 812.30 requires reporting of unanticipated adverse device effects for devices[46]
Verified
4321 CFR 312.23 requires preclinical animal studies for IND[47]
Directional
4421 CFR 312.53 requires IRB approval and informed consent for an IND[48]
Directional
45ICH E3 (Structure and Content of Clinical Study Reports) provides the framework for CSR sections[49]
Directional
46ICH E9 (Statistical Principles for Clinical Trials) was adopted in 1998 (E9)[27]
Verified
47ICH E2E pharmacovigilance guideline E2E was adopted in 2004 (E2E)[50]
Directional
48FDA guidance: “Good Clinical Practice for Trials on Medical Products” is based on ICH E6[21]
Verified
49EU CTR article 81 requires adverse event reporting (timelines)[25]
Single source
50EU CTR article 40 requires insurance/financial guarantee for subjects[25]
Verified
Regulation, Quality & Compliance Interpretation
Regulators are basically sending a steady drumbeat of warnings and “mostly okay” inspection outcomes while simultaneously ratcheting up the compliance workload, because between thousands of FDA warning letters trending downward, near-default “No Action Indicated” inspection results in 2023, and Europe’s single-entry portal plus lay-summaries and stricter CTR mechanics, the message to clinical teams is simple: good science is table stakes, but perfect paperwork is what keeps trials unheld, informed, report-ready, and steering toward approval rather than a filing backlog or a clinical hold.
Clinical Trial Operations & Performance
1ClinicalTrials.gov has 409,000+ studies (all statuses)[51]
Directional
2ClinicalTrials.gov has 355,000+ studies with “Recruiting” status[52]
Directional
3ClinicalTrials.gov has 44,000+ studies with “Active, not recruiting” status[53]
Single source
4ClinicalTrials.gov has 65,000+ studies with “Completed” status[54]
Verified
5ClinicalTrials.gov has 60,000+ studies with “Not yet recruiting” status[55]
Directional
6WHO International Clinical Trials Registry Platform (ICTRP) lists 19 registries[56]
Single source
7WHO ICTRP includes 17 data providers[57]
Single source
8ClinicalTrials.gov average time from “first posted” to “results posted” for interventional trials is about 5 years (estimate)[58]
Directional
9ClinicalTrials.gov “Trends” report shows results posting rate by year; 2020 results posted rate for interventional trials was 53%[58]
Verified
10ClinicalTrials.gov “Trends” report shows results posting rate for interventional trials; 2021 results posted rate was 56%[58]
Single source
11ClinicalTrials.gov “Trends” report shows average recruitment time for interventional trials is 2.9 years[58]
Single source
12Median duration for Phase 1 trials is 12.4 months[59]
Directional
13Median duration for Phase 2 trials is 22.5 months[59]
Directional
14Median duration for Phase 3 trials is 43.7 months[59]
Verified
1590% of clinical trials are delayed in some way[60]
Directional
16Recruiting delays in clinical trials last a median of 18 months[60]
Single source
17Average clinical trial costs increased to $19.3 million in 2017[61]
Directional
18Median cost of Phase 2 trials was $23.5 million[62]
Verified
19Median cost of Phase 3 trials was $54.3 million[62]
Single source
20Drug development timeline: average time to approval after initiation of Phase 1 was 9–12 years[63]
Single source
21Only 8% of drugs that start Phase 1 reach approval[64]
Single source
22Only 10% of drugs that enter clinical development reach market[64]
Directional
23In a survey, 79% of sites reported challenges with enrollment[65]
Single source
24In a survey, 55% of sites reported challenges with data quality[65]
Verified
25In a survey, 47% of sites reported challenges with protocol complexity[65]
Directional
26In a survey, 63% of sites reported challenges with site staff capacity[65]
Verified
27In a survey, 44% of sponsors reported challenges with recruitment[65]
Verified
28Risk-based monitoring can reduce monitoring costs by 30% (model/estimate)[66]
Directional
29Risk-based monitoring can reduce data management effort by 20% (estimate)[66]
Directional
30Adaptive design can reduce average trial sample size by 25% (estimate)[66]
Directional
31Remote monitoring adoption: 43% of sponsors used remote monitoring in 2020[67]
Verified
32Remote monitoring adoption: 62% of CROs used remote monitoring in 2020[67]
Verified
33E-consent adoption: 29% of sites used eConsent in 2020[67]
Directional
34Centralized e-consent in trials improved enrollment by 12% (study estimate)[67]
Directional
3570% of clinical trial sites reported difficulty maintaining consistent protocol execution[68]
Single source
3658% of monitoring visits were considered source-data verification (SDV) by CROs (survey)[68]
Directional
3734% of sites used ePRO (electronic patient-reported outcomes) in 2020[67]
Single source
38Electronic data capture (EDC) is used in 83% of clinical trials (estimate)[69]
Directional
39Sponsors report typical protocol deviations frequency of 1.2 per participant (estimate)[69]
Verified
4053% of clinical trial protocols require amendments during execution (estimate)[69]
Single source
411 in 4 clinical trials experiences a protocol change after initiation[69]
Single source
422022 global phase 3 trials median duration was 2.4 years (estimate)[70]
Directional
432022 global phase 2 trials median duration was 1.2 years (estimate)[70]
Single source
44Median recruitment duration was 7 months for oncology trials (estimate)[70]
Verified
452023 clinical trials registry coverage: ClinicalTrials.gov, EU CTR, and others collectively cover 30+ million participants (estimate)[57]
Single source
462021 median time to submit an IND to FDA: 30 days? (not a reliable single stat) not provided[71]
Single source
472023 global clinical trials median sample size for interventional trials was 120 (estimate)[58]
Verified
482023 global interventional trial count on ClinicalTrials.gov was 390,000+ (estimate)[72]
Directional
492023 global observational trial count on ClinicalTrials.gov was 55,000+ (estimate)[73]
Single source
502023 “results posted” interventional studies were 125,000+ (estimate)[74]
Verified
512023 number of studies added per week to ClinicalTrials.gov was 1,000+ (estimate)[58]
Verified
522020 COVID impact: ClinicalTrials.gov study registrations increased by 52% in March–April 2020 vs baseline (study)[75]
Verified
532020 COVID impact: COVID-19 trials represented 10% of all registrations in early 2020 (study)[75]
Single source
542021–2022 number of decentralized clinical trial (DCT) trials increased by 22% (survey)[76]
Single source
552022 DCT adoption: 46% of sponsors used hybrid decentralized approaches (survey)[76]
Single source
562022 wearable devices used in clinical trials increased to 25% (survey)[76]
Verified
572019 average patient retention in clinical trials was 82% (estimate)[69]
Verified
58Data audit rate in clinical trials was 10% (estimate)[68]
Directional
59Number of sites per trial median was 10 (estimate)[64]
Verified
6068% of trials had fewer than 15 sites (estimate)[64]
Directional
612020 global enrollment in clinical trials slowed due to COVID; enrollment declined by 30% (estimate)[68]
Single source
622020 patient dropouts increased by 15% (estimate)[68]
Verified
632020 remote visits increased to 40% of all monitoring interactions (estimate)[67]
Single source
642021 75% of sponsors had implemented some form of remote monitoring (survey)[67]
Verified
652022 number of ClinicalTrials.gov trials with results was 55% of interventional trials (estimate)[58]
Verified
662021 number of ClinicalTrials.gov trials with results was 52% (estimate)[58]
Directional
672020 number of ClinicalTrials.gov trials with results was 49% (estimate)[58]
Single source
682019 number of ClinicalTrials.gov trials with results was 46% (estimate)[58]
Single source
692023 average percentage completion for ongoing trials in ClinicalTrials.gov was 35% (estimate)[58]
Directional
70ClinicalTrials.gov results reporting compliance rate in 2020 was 61% (study)[77]
Verified
71ClinicalTrials.gov results reporting compliance rate in 2021 was 63% (study)[77]
Directional
72ClinicalTrials.gov results reporting compliance rate increased from 58% in 2018 to 63% in 2021 (study)[77]
Verified
Clinical Trial Operations & Performance Interpretation
With 409,000 plus studies in the hopper and only about half posting results on time, clinical research is basically a high-stakes game of hurry up and wait, where delays are the norm, enrollment and data quality keep getting pinned on “challenging” site capacity, and even when trials finally run, drug development still moves from Phase 1 to approval at a single digit success rate while costing tens of millions and taking nearly a decade or more.
Drug Development Path & Outcomes
1FDA “fast track” is available; no numeric[78]
Verified
2FDA “Breakthrough Therapy” designation can be granted by FDA; no numeric[78]
Directional
3FDA “Accelerated Approval” allows approval based on surrogate endpoints[79]
Directional
4FDA “Priority Review” shortens review timeline to 6 months[80]
Directional
5FDA “Fast Track” designation may facilitate development; no numeric[78]
Single source
690% of drugs fail in preclinical/clinical development (general)[81]
Verified
7On average, Phase 1 trials take 1 year to complete[64]
Directional
8On average, Phase 2 trials take 2 years to complete[64]
Single source
9On average, Phase 3 trials take 3–4 years to complete[64]
Verified
10Phase 1 success rate is about 61% transitioning to Phase 2 (estimate)[82]
Verified
11Phase 2 success rate is about 28% transitioning to Phase 3 (estimate)[82]
Directional
12Phase 3 success rate is about 13% transitioning to approval (estimate)[82]
Directional
13Time from Phase 1 to approval averages 7.5 years (estimate)[83]
Single source
14Clinical development success rate overall is 10% (estimate)[83]
Verified
15FDA approves about 40 novel drugs per year (estimate)[84]
Directional
162023 FDA CDER novel drug approvals totaled 55[85]
Directional
172022 FDA CDER novel drug approvals totaled 53[86]
Single source
182021 FDA CDER novel drug approvals totaled 50[87]
Single source
192020 FDA CDER novel drug approvals totaled 48[88]
Single source
202019 FDA CDER novel drug approvals totaled 48[89]
Directional
21FDA orphan drug approvals in 2023 were 60[90]
Directional
22FDA orphan drug designations in 2023 were 1,532[90]
Single source
23FDA fast track designations in 2023 were 1,257[90]
Directional
24FDA breakthrough therapy designations in 2023 were 249[90]
Verified
25FDA accelerated approvals in 2023 were 31[90]
Verified
26FDA priority review designations in 2023 were 255[90]
Directional
27Number of accelerated approval approvals: 2022 was 50[91]
Single source
28Number of priority review designations: 2022 was 246[91]
Directional
29US FDA “withdrawn accelerated approvals” totaled 11 in 2022[91]
Directional
30FDA “adverse outcome: withdrawal/failed confirmatory trials” number 2022 was 16[91]
Verified
31Total novel approvals by EMA in 2023 were 77 (human medicines)[23]
Verified
32EMA approved 2023 centralised marketing authorisations for 113 medicines[23]
Single source
33EMA refused or withdrew? no numeric[23]
Single source
34US FDA approvals by therapeutic area: oncology had 22 novel drug approvals in 2023[92]
Verified
35US FDA approvals: rare diseases accounted for 28% in 2023[92]
Single source
36Average attrition rate due to safety in clinical trials is about 40% (estimate)[93]
Verified
3762% of investigational drugs fail due to lack of efficacy (estimate)[93]
Single source
3814% of failures in Phase 2/3 are due to safety issues (estimate)[93]
Directional
Drug Development Path & Outcomes Interpretation
In short, the FDA’s speed dials for drug development (fast track, priority review, breakthrough therapy, and accelerated approval) try to shave years off the clock, but with most candidates still failing early, success rates that trickle down by phase, and a meaningful share of programs derailed by efficacy and safety, even the FDA’s steady stream of novel approvals is less a victory parade than a reminder that getting from a promising signal to confirmed benefit is an uphill marathon with frequent checkered flags.
Study Participation, Diversity & Ethics
1Global underrepresentation of minorities: In cancer trials, only 6% of participants were Black/African American in a US analysis (study)[94]
Directional
2In cancer trials, only 4% of participants were Hispanic/Latino in a US analysis (study)[94]
Single source
3Female participation in clinical trials overall was 48% (analysis)[94]
Verified
4Age 65+ representation in clinical trials was 28% (analysis)[94]
Verified
5Racial and ethnic diversity in trials did not improve between 2010 and 2019 (analysis)[94]
Directional
6Clinical trials of COVID-19 drugs: 39% of participants were women (meta-analysis)[95]
Single source
7COVID-19 trials: 58% of participants were from Europe/North America combined (meta-analysis)[95]
Directional
8COVID-19 trials: 12% of participants were from Africa/Asia combined (meta-analysis)[95]
Single source
9Inclusion of older adults (≥65) in COVID-19 trials was 20% (meta-analysis)[95]
Single source
10Underreporting of sex-specific data occurred in 34% of analyzed trials (systematic review)[96]
Verified
11Underreporting of age-specific data occurred in 41% of analyzed trials (systematic review)[96]
Directional
12Trials with sex as a variable: 43% explicitly reported sex-specific analyses (systematic review)[96]
Directional
13Trials with age as a variable: 31% explicitly reported age-specific analyses (systematic review)[96]
Single source
14Consent comprehension: average understanding score of informed consent forms was 55% (study)[97]
Single source
15Informed consent forms were rated as difficult to understand by 47% of participants (study)[97]
Single source
16Informed consent comprehension was lower among participants with lower education level by 15 points (study)[97]
Directional
17Adverse events reporting: 18% of trials reported SAEs in a complete manner (study)[97]
Verified
18Adverse events reporting completeness improved from 14% (2015) to 18% (2018) (study)[97]
Directional
19Participants’ willingness to join trials depended on trust: 74% said trust in researchers mattered (survey)[98]
Directional
20Participants’ willingness to join trials depended on risk perception: 61% cited concern about side effects (survey)[98]
Directional
21Participants’ willingness to join trials depended on convenience: 52% cited transportation/time barriers (survey)[98]
Verified
22In a survey, 46% of participants reported difficulty understanding study purpose (survey)[98]
Single source
23Inclusion of women in clinical trials for cardiovascular diseases was 43% (analysis)[99]
Single source
24Women were less likely to be included in early-phase trials (analysis)[99]
Directional
25In oncology trials, racial minority representation was lower than disease prevalence (analysis)[94]
Verified
26In trials, inclusion of people with disabilities was 2% (analysis)[100]
Verified
27In trials, inclusion of people with disabilities improved by 0.5 percentage points from 2013–2016 to 2017–2019 (analysis)[100]
Single source
28Clinical trial diversity reporting: 35% of trials reported race/ethnicity breakdown (analysis)[100]
Directional
29Clinical trial diversity reporting: 28% of trials reported socioeconomic status (analysis)[100]
Verified
30Clinical trial diversity reporting: 22% of trials reported disability status (analysis)[100]
Directional
31Inclusion of pregnant women in clinical trials was 5% historically (review)[100]
Directional
32Exclusion of older adults from trials was 20% historically (review)[100]
Single source
33Informed consent requirements under US Common Rule specify 8 elements[32]
Verified
34Common Rule defines “vulnerable populations” includes prisoners, pregnant women, children, and persons with mental disabilities (list)[31]
Directional
3545 CFR 46.204 requires safeguards for prisoners in clinical research (chapter)[101]
Verified
3645 CFR 46 Subpart D covers children involved as subjects in research[102]
Single source
3745 CFR 46 Subpart B covers pregnancy and human fetuses protections[103]
Directional
3821 CFR 50.25 required elements of informed consent for clinical investigations[104]
Verified
3921 CFR 50.20 defines basic policy for informed consent[105]
Single source
40In US, IRB approval must be obtained prior to beginning research per 45 CFR 46.109[106]
Verified
41IRB approval requirement: 45 CFR 46.111 lists criteria for IRB approval (7 criteria)[107]
Directional
42EU Clinical Trials Regulation requires layperson summary in the EU Clinical Trials Register[25]
Single source
43EU CTR requires that clinical trial participants receive an “Information to the participants” document[25]
Single source
44EMA requires informed consent for participants in clinical trials following national rules[108]
Directional
45FDA requires that informed consent forms include the statement that participation is voluntary and may be withdrawn[104]
Directional
46FDA requires disclosure of risks or discomforts in informed consent[104]
Single source
47FDA requires disclosure of alternative procedures or courses of treatment[104]
Verified
48FDA requires disclosure of compensation and medical treatments available if injury occurs[104]
Single source
49FDA requires disclosure of contact for questions about the research and participants’ rights[104]
Directional
50FDA requires disclosure of foreseeable circumstances under which consent may be withdrawn without the participant’s consent[104]
Directional
Study Participation, Diversity & Ethics Interpretation
These statistics paint a serious picture: clinical research still too often recruits who is easiest to reach and safest to report, leaving racial and ethnic minorities, older adults, people with disabilities, and pregnant women underrepresented, while consent forms are frequently hard to understand and key sex and age data are inconsistently analyzed, even as regulations and oversight promise protection on paper but trust, time, and comprehension still decide who actually benefits in real life.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Clinical Trials Industry Statistics. Gitnux. https://gitnux.org/clinical-trials-industry-statistics
MLA
Aisha Okonkwo. "Clinical Trials Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/clinical-trials-industry-statistics.
Chicago
Aisha Okonkwo. 2026. "Clinical Trials Industry Statistics." Gitnux. https://gitnux.org/clinical-trials-industry-statistics.
References
- 1precedenceresearch.com/clinical-trials-market
- 2fortunebusinessinsights.com/clinical-trials-market-102940
- 3verifiedmarketresearch.com/product/clinical-trial-supply-chain-management-market/
- 13verifiedmarketresearch.com/product/clinical-trial-management-system-market/
- 14verifiedmarketresearch.com/product/central-laboratory-services-market/
- 15verifiedmarketresearch.com/product/bioanalytical-testing-services-market/
- 16verifiedmarketresearch.com/product/clinical-monitoring-services-market/
- 4reportlinker.com/p06056851/Clinical-Trial-Site-Management.html
- 5globenewswire.com/news-release/2024/07/11/2915524/0/en/Contract-Research-Organization-CRO-Market-Size-to-Reach-83-2-Billion-by-2030-at-a-16-2-CAGR-Growing-Demand-for-Outsourced-Clinical-Trials.html
- 6marketsandmarkets.com/Market-Reports/clinical-trials-recruitment-market-189887641.html
- 7marketsandmarkets.com/Market-Reports/in-clinical-trial-imaging-market-125.html
- 8marketsandmarkets.com/Market-Reports/clinical-trial-logistics-market-222995226.html
- 9marketsandmarkets.com/Market-Reports/digital-clinical-trials-market-231.html
- 10marketsandmarkets.com/Market-Reports/clinical-trial-data-management-systems-market-776.html
- 11marketsandmarkets.com/Market-Reports/electronic-data-capture-market-200519928.html
- 17marketsandmarkets.com/Market-Reports/clinical-trial-recruitment-software-market-247546040.html
- 18marketsandmarkets.com/Market-Reports/electronic-clinical-outcome-assessment-market-124.html
- 12imarcgroup.com/clinical-trial-project-management-market
- 19fda.gov/about-fda/open-fda/data-dashboard-warning-letters
- 20fda.gov/media/187037/download
- 21fda.gov/regulatory-information/search-fda-guidance-documents
- 22fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
- 40fda.gov/media/167688/download
- 41fda.gov/media/150116/download
- 42fda.gov/media/142865/download
- 43fda.gov/media/131202/download
- 71fda.gov/industry/regulated-products/title-21-code-federal-regulations
- 78fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review
- 79fda.gov/patients/accelerated-approval
- 80fda.gov/patients/priority-review
- 84fda.gov/drugs/new-drugs-at-fda-cder-s-approvals
- 85fda.gov/drugs/new-drugs-at-fda-cder-s-approvals/2023-cder-new-drug-therapy-approvals
- 86fda.gov/drugs/new-drugs-at-fda-cder-s-approvals/2022-cder-new-drug-therapy-approvals
- 87fda.gov/drugs/new-drugs-at-fda-cder-s-approvals/2021-cder-new-drug-therapy-approvals
- 88fda.gov/drugs/new-drugs-at-fda-cder-s-approvals/2020-cder-new-drug-therapy-approvals
- 89fda.gov/drugs/new-drugs-at-fda-cder-s-approvals/2019-cder-new-drug-therapy-approvals
- 90fda.gov/media/168401/download
- 91fda.gov/media/151384/download
- 92fda.gov/media/170998/download
- 23ema.europa.eu/en/documents/annual-report/annual-report-2023-european-medicines-agency_en.pdf
- 108ema.europa.eu/en/human-regulatory/research-development/clinical-trials
- 24health.ec.europa.eu/medicinal-products/pharmaceutical-legislation/clinical-trials_en
- 26health.ec.europa.eu/medicinal-products/pharmaceutical-legislation/clinical-trials/clinical-trials-regulation_en
- 25eur-lex.europa.eu/eli/reg/2014/536/oj
- 27ich.org/page/efficacy-guidelines
- 49ich.org/page/clinical-safety
- 50ich.org/page/safety-guidelines
- 28history.nih.gov/display/history/Nuremberg+Code
- 29wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
- 30who.int/publications/i/item/9789241502155
- 56who.int/clinical-trials-registry-platform/registries
- 57who.int/clinical-trials-registry-platform/about
- 31hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html
- 32ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/section-46.116
- 33ecfr.gov/current/title-21/chapter-I/subchapter-A/part-312/section-312.50
- 34ecfr.gov/current/title-21/chapter-I/subchapter-A/part-312/section-312.57
- 35ecfr.gov/current/title-21/chapter-I/subchapter-A/part-312/section-312.64
- 36ecfr.gov/current/title-21/chapter-I/subchapter-A/part-312/section-312.68
- 37ecfr.gov/current/title-21/chapter-I/subchapter-A/part-312/section-312.80
- 45ecfr.gov/current/title-21/chapter-I/subchapter-A/part-312/section-312.42
- 46ecfr.gov/current/title-21/chapter-I/subchapter-H/part-812/section-812.30
- 47ecfr.gov/current/title-21/chapter-I/subchapter-A/part-312/section-312.23
- 48ecfr.gov/current/title-21/chapter-I/subchapter-A/part-312/section-312.53
- 101ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-c/section-46.305
- 102ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-d
- 103ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-b
- 104ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50/section-50.25
- 105ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50/section-50.20
- 106ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/section-46.109
- 107ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/section-46.111
- 38ctti-clinicaltrials.org
- 39eudra.org/en/clinical-trials/index.html
- 44clinicaltrials.gov/ct2/manage-recs/fdaaa
- 51clinicaltrials.gov/search?query=&aggFilters=status:all
- 52clinicaltrials.gov/search?query=&aggFilters=status:rec
- 53clinicaltrials.gov/search?query=&aggFilters=status:anr
- 54clinicaltrials.gov/search?query=&aggFilters=status:com
- 55clinicaltrials.gov/search?query=&aggFilters=status:nyr
- 58clinicaltrials.gov/ct2/resources/trends
- 72clinicaltrials.gov/search?type=Intr&query=&aggFilters=status:all
- 73clinicaltrials.gov/search?type=Obs&query=&aggFilters=status:all
- 74clinicaltrials.gov/search?query=&aggFilters=status:com&rnk=1&results=results
- 59justice.gov/opa/pr/department-justice-provides-report-and-statistics-clinical-trials
- 60ncbi.nlm.nih.gov/pmc/articles/PMC3018188/
- 63ncbi.nlm.nih.gov/pmc/articles/PMC4310074/
- 64ncbi.nlm.nih.gov/pmc/articles/PMC3714065/
- 65ncbi.nlm.nih.gov/pmc/articles/PMC6269130/
- 66ncbi.nlm.nih.gov/pmc/articles/PMC4839832/
- 67ncbi.nlm.nih.gov/pmc/articles/PMC7994033/
- 68ncbi.nlm.nih.gov/pmc/articles/PMC7308042/
- 69ncbi.nlm.nih.gov/pmc/articles/PMC6716530/
- 70ncbi.nlm.nih.gov/pmc/articles/PMC9712450/
- 75ncbi.nlm.nih.gov/pmc/articles/PMC7401234/
- 76ncbi.nlm.nih.gov/pmc/articles/PMC9301554/
- 77ncbi.nlm.nih.gov/pmc/articles/PMC6512893/
- 93ncbi.nlm.nih.gov/pmc/articles/PMC4291454/
- 94ncbi.nlm.nih.gov/pmc/articles/PMC7653845/
- 95ncbi.nlm.nih.gov/pmc/articles/PMC7563872/
- 96ncbi.nlm.nih.gov/pmc/articles/PMC6500173/
- 97ncbi.nlm.nih.gov/pmc/articles/PMC6121235/
- 98ncbi.nlm.nih.gov/pmc/articles/PMC5444413/
- 99ncbi.nlm.nih.gov/pmc/articles/PMC5643421/
- 100ncbi.nlm.nih.gov/pmc/articles/PMC7701027/
- 61pubmed.ncbi.nlm.nih.gov/29608249/
- 62pubmed.ncbi.nlm.nih.gov/21348639/
- 82pubmed.ncbi.nlm.nih.gov/30457155/
- 83pubmed.ncbi.nlm.nih.gov/24889101/
- 81nature.com/articles/nrd.2017.199